A Phase III, Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of Intravenous L-Citrulline in Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis in Children, Adolescents and Young Adults (6 to 21 Years)

This study is being done to learn more about a possible new treatment for pain episodes (called vaso-occlusive crises or VOCs) in children, teens, and young adults with sickle cell disease (SCD). The study will include about 120 participants between the ages of 6 and 21 who come to the emergency department (ED) with a VOC.
A VOC is a painful episode that happens with no clear cause and no signs of infection or major problems with organs like the liver or kidneys.
Before joining the study, patients and their families may be asked to learn about it and give permission (called consent or assent) while at a regular clinic visit. If that hasn't happened yet, the consent/assent process will happen at the emergency department when the patient comes in for care. If the patient meets all the study requirements, they can join the treatment part of the study.
Participants will be randomly assigned (like flipping a coin) to receive either:
L-citrulline, the study drug, or A placebo, which looks the same but has no active ingredients.
Everyone has an equal chance of getting either one. The study drug is given through an IV. It starts with one larger dose, followed by a steady infusion for up to 12 hours.
All patients in the study will still receive the usual pain treatment (called standard of care), which may include opioids. However, some patients may need fewer opioids if the study treatment helps with their pain.
If any medicines are not allowed during the study, the doctor will explain this during the consent process.
Patients can go home once:
Their pain is controlled with oral (by mouth) pain medicine, They're eating and drinking well, and They've been given a personal pain management plan to use at home.
After leaving the hospital, the study team will follow up with patients by phone about 2 days later (within a 12-hour window), again around Day 7, and again around Day 30 to check how they're doing.

Start Date25 Jul 2025

Sponsor / Collaborator

Asklepion Pharmaceuticals LLC

NCT06426147

/ Not yet recruitingNot ApplicableIIT

A Randomised, Double-blind, Placebo-controlled Trial of L-Citrulline Oral Supplementation to Improve Short and Long-term Outcomes of Admitted Febrile Paediatric Patients With Biomarker-determined High-risk of Adverse Outcomes

In low and middle-income countries, children admitted to hospital are not similarly ill, and do not all have a comparable prognosis. In fact, understanding at first encounter their risk of developing adverse outcomes (including mortality) could allow a more focused management and the tailoring of specific interventions to decrease in hospital mortality, and post discharge adverse longer-term outcomes. This clinical trial, part of the EChiLiBRiST larger project ("Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival") has the two-fold objective of:
1. Assessing whether a POINT-OF-CARE rapid triaging test (PoC RTT) based on the quantitative measurement at the bedside of the "prognostic" biomarker sTREM-1 (soluble-triggering receptor expressed on myeloid cells 1) can reliably identify those admitted children with a higher risk of adverse outcomes; and
2. Assessing whether the therapeutic intervention (the L-arginine precursor, L-Citrulline, key in the nitric oxide biosynthesis), administered orally for 28 days to those children aged 1-<60 months identified as "moderate-to-high risk" by the prognostic biomarker can improve outcomes as compared to those receiving an indistinguishable placebo.
This second objective will be assessed in a prospective multi-country, multi-site, individually randomised, two-arm, placebo-controlled, double blind clinical trial involving
888 children 1-<60m of age admitted to hospital and determined to be at high risk of adverse outcomes by their baseline sTREM-1 levels. The trial will compare the efficacy of a twice-daily dose of L-citrulline syrup vs placebo (200-300mg/kg/day depending on weight-band; for 28 days) in reducing adverse outcomes in children with severe disease. The trial will be running independently but in parallel in two high-mortality settings in Mozambique and in Ethiopia.

Start Date01 Jan 2025

Sponsor / Collaborator

Barcelona Institute for Global Health

NCT06635902

/ RecruitingPhase 2IIT

A Phase 2 Randomized Double-blind, Placebo-controlled Clinical Trial of Intravenous Citrulline for Vaso-occlusive Pain Episode in Hospitalized Patients With Sickle Cell Disease (CONQUER SCD Pain Trial)

The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are:
* Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization
* What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-alike substance that contains no drug) to see if intravenous citrulline works to treat acute pain.
Participants will:
* Receive baseline tests and intravenous citrulline for 16 hours during the hospital stay
* After hospital discharge, visit the clinic in about 30 days for checkup and tests

Start Date22 Dec 2024

Sponsor / Collaborator

Children's National Research Institute

[+1]

100 Clinical Results associated with L-Citrulline

100 Translational Medicine associated with L-Citrulline

100 Patents (Medical) associated with L-Citrulline

11,513

Literatures (Medical) associated with L-Citrulline

01 Sep 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Visualizing the spatial distribution of functional metabolites in the root of Codonopsis pilosula: An investigation integrating metabolomics, serum pharmacochemistry, and MALDI-MSI

Article

Author: He, Yan ; Li, Tongtong ; Fan, Boyi ; Wu, Xinjie ; Gao, Jianping ; He, Hui ; Tong, Tong ; Xu, Jinfang

Codonopsis pilosula is a traditional Chinese tonic herb commonly used as food and medicine, particularly for the treatment of spleen deficiency syndrome. However, the specific bioactive components responsible for C. pilosula effects remain unclear, and their distribution in the root of C. pilosula has not been fully elucidated due to the lack of efficient analytical techniques. In this work, we combined metabolomics with serum pharmacochemistry to investigate C. pilosula effects in a rat model of spleen deficiency syndrome. Pearson correlative analysis was applied to discover that 8 chemical compounds, including lobetyolin, atractylenolide III, syringin, luteolin, asperuloside, O-acetyl-L-serine, L-citrulline and creatine, were significantly correlated with biomarkers and considered as potential pharmacodynamic basis of C. pilosula. Furthermore, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was performed to visualize the spatial distribution of the bioactive substances in the root of C. pilosula. L-citrulline was widely distributed in roots. The content of atractylenolide III and luteolin in the cortex and xylem was much higher than that in the phloem. O-Acetyl-L-serine was present in the entire phloem and a small portion of the xylem. Creatine, lobetyolin, asperuloside, and syringin were mostly distributed in the peridermal cortex, and their contents were low. By integrating metabolomics, serum pharmacochemistry and MALDI-MSI, our proposed analytical method elucidated the material basis of C. pilosula and figured out their spatial distribution in the root of C. pilosula, which provides new insights for improving the quality of medicinal herbs.

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A predictive metabolomic model for FLT3 and NPM1 mutations in Acute Myeloid Leukemia patients

Article

Author: Toprak, Selami Koçak ; Özcan, Muhit ; Gerekci Yeşi Lyurt, Selin ; Özen, Can ; Koyun, Derya

Cytogenetic abnormalities and gene mutations are essential for planning AML treatment. However, in Turkey, test results typically take 14-30 days. This delay emphasizes a critical need for rapid methods to deliver clinical data in urgent cases requiring immediate treatment decisions. To address this need, our objective was to develop a quick prediction method for NPM1 (Nucleophosmin-1) and FLT3 (FMS-like tyrosine kinase 3) mutations using LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) targeted metabolomics to detect these common and clinically important mutations in de novo AML patients (n = 42) through patient groups and a healthy group. We analyzed metabolic patterns using LC-MS/MS measurements of amino acids and acyl carnitines, key components critical to AML prognosis. The data were then subjected to multivariate analysis techniques. Principal Component Analysis (PCA) revealed that the model explained 79 % of the total variance among the sample groups. To further enhance class discrimination, we conducted Partial Least Squares-Discriminant Analysis (PLS-DA), resulting in R2Y and Q2 values of 0.845 and 0.619, respectively. Using the PLS-DA model, VIP (Variable Importance Projection) identified key metabolites with scores > 1.5, including C0 carnitine, glutamic acid, aspartic acid, tryptophan, histidine, isoleucine, and alpha-aminobutyric acid, respectively, highlighting their potential significance in distinguishing mutation groups. To ensure the validity of the PLS-DA model and evaluate potential overestimation, we validated the model using cross-validation and permutation test, demonstrating its robustness and reliability. Our preliminary model, developed through a targeted metabolomics approach, shows strong fit and predictive capability in determining the mutation status of NPM1 and FLT3 in AML patients.

01 Aug 2025·FOOD CHEMISTRY

Metabolomics unravels the formation pathway of advanced glycation end products in preserved egg yolk mediated by OH− during pickling

Article

Author: Xiang, Xiaole ; Dong, Shiqin ; Li, Shugang ; Huang, Yiqun ; Yu, Zhuosi ; Ye, Lin ; Chen, Le ; He, Yu

Metabolomics was first applied to explore the formation pathway and regulatory factors for advanced glycation end products (AGEs) in preserved egg yolk (PEY) during pickling. Most reactions that contributed to formation of AGEs, including oxidation and/or degradation of matrix/precursors and Maillard reaction, occurred primarily in PEY in early stage, and lipid oxidation occurred prior to protein oxidation. Additionally, the formation of N^ε-carboxymethyl-lysine (CML) in PEY was mainly attributed to glyoxal derived from D-glucuronic acid in early stage based on the correlation between metabolites and AGEs. Reactive oxygen radicals from oxidized lipids also promoted the enrichment of CML and N^ε-carboxymethyl-lysine (CEL). Moreover, during later stage, the accumulation of CEL was enhanced through methylglyoxal from Schiff bases, and acidic compounds could inhibit AGEs via hindering Maillard reaction. This manuscript pioneered the application of metabolomics to reveal the formation pathway of AGEs, and will provide new perspective on AGEs formation in foods.

News (Medical) associated with L-Citrulline

05 Oct 2023

·www.prnewswire.com

Bizz Energy Is a Clean, Mean Way to Beat the Modern Midday Slump

The Energy Drink Formula Unleashes Unique Levels of Energy Whilst Avoiding Sugar Crashes and Unhealthy Ingredients FORT LAUDERDALE, Fla., Oct. 5, 2023 /PRNewswire/ -- The modern, remote-first work world may not have a consistent nine-to-five rhythm anymore. But that doesn't change the fact that people are still putting a lot of time into working their jobs. The Bureau of Labor Statistics reports that the average American worker clocks in at just over eight hours of labor per day (8.01, to be precise). That means, no matter when those work hours take place, they're going to extend over a significant portion of an individual's daily schedule. It also means it will involve a slump in energy and productivity at some point along the way. "Midday slumps may not always happen in the early afternoon anymore," says Gavin Jacono, founder of Bizz Energy, "But they happen at some point — and on a regular basis. If you start work at four in the morning, chances are you're going to lag after breakfast or in the late morning. If you start at noon, you'll feel tired before dinner." Northwestern Medicine points out that the biggest reason for this energy slump is that it's a predictable part of every individual's circadian cycle. However, the medical site adds that things like sleep disorders, stress, and even poor eating habits can also contribute to a slowdown in the middle of the workday. When that happens, many people turn to energy drinks as a solution — but Jacono points out that traditional energy drink formulas don't really solve the problem. "Those classic formulas use sugar, high fructose corn syrup, or aspartame. They give you a quick boost, but it's often followed by a crash — usually before your work day ends, which only means you're kicking the productivity issue down the road. And your body has to work through all of those unhealthy chemicals and additives, too. That's why we created Bizz Energy. To turn unhealthy, short-term energy drinks into healthy, long-term productivity and health solutions." Bizz Energy replaces unwanted ingredients with healthy alternatives. Each 12 oz can contains a clean shot of 200 mg of caffeine along with a punchy nutritional combination called the SuperTurk® blend. This includes an innovative soluble form of Turkesterone along with creatine, essential amino acids, L-citrulline, L-theanine, L-carnitine, niacin, and biotin. The result of this revolutionary combination is an energy drink that doubles as a nutritional supplement. It helps boost energy without a sugar crash while also stimulating metabolism and helping build muscle and strength. This makes it a clean, mean way to beat a midday slump — no matter when it might take place. About Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Media Contact: Gavin Jacono 516-637-8701 [email protected] SOURCE Bizz Energy

04 Aug 2023

·www.prnewswire.com

Bizz Energy Clears Minds and Sharpens Focus

The Clean, Zero-Sugar Energy Drink Is Good For More Than Just Physical Performance. It Boosts Brain Function, Too. FORT LAUDERDALE, Fla., Aug. 4, 2023 /PRNewswire/ -- Bizz Energy is a revolutionary new zero-sugar energy drink designed to boost performance through natural ingredients without the use of harmful chemicals or additives. While this is primarily focused on physical activities, the energy supplement's ingredients can also deliver some helpful benefits for the brain. "I designed Bizz Energy to clear my mind as well as boost my physical performance," explains company founder Gavin Jacono. "Sometimes you need to do more than run faster, lift more, or stay awake longer. Sometimes you need that sharp focus that helps you deliver at work or in school." Bizz Energy helps with cognitive function through multiple natural ingredients. For instance, creatine is a safe brain and body amino acid that has been connected to short-term memory improvement when administered orally. L-citrulline has clearly demonstrated benefits for brain function, as well. L-Theanine relieves stress disorders, improves mood, and helps with sleep. Another ingredient with the potential to help with cognition is Turkesterone. While this popular supplement is currently trending in the sports and fitness world for its physical benefits, there are also suggestions that it could aid mental health by helping cope with stress and fatigue. "Including Turkesterone was a big deal for us," says Jacono. "I knew we wanted it in there, but it's a plant-based steroid, so it isn't water-soluble. We invested in extensive research and testing and were able to develop a method to solubilize Turkesterone — it's one of the most unique things about our product." From carefully selected amino acids to soluble Turkesterone, Bizz Energy is packed with natural ingredients designed to deliver a critical dose of energy when needed. The innovative combination of natural ingredients doesn't just apply to physical performance, either. It can be a game-changer when it comes to cognitive function, too, helping to sharpen the mind and create clear focus. About Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Media Contact: Gavin Jacono 516-637-8701 [email protected] SOURCE Bizz Energy

05 Dec 2022

·www.sciencedaily.com

Not all micronutrients created equal: Study identifies some supplements that benefit cardiovascular health

Healthy diets are rich in antioxidants like amino acids, omega-3 fatty acids and vitamin C, but exactly how beneficial these micronutrients are for cardiovascular health has long been controversial. Now a new meta-analysis provides some clarity. Healthy diets are rich in antioxidants like amino acids, omega-3 fatty acids and vitamin C, but exactly how beneficial these micronutrients are for cardiovascular health has long been controversial. Now a new meta-analysis published in the Journal of the American College of Cardiology provides some clarity. Researchers systematically reviewed a total of 884 studies available to date on micronutrients taken as dietary supplements and analyzed their data. They identified several micronutrients that do reduce cardiovascular risk -- as well as others that offer no benefit or even have a negative effect. More than 883,000 patients were involved in the combined studies. "For the first time, we developed a comprehensive, evidence-based integrative map to characterize and quantify micronutrient supplements' potential effects on cardiometabolic outcomes," said Simin Liu, MD, MS, MPH, ScD, professor of epidemiology and medicine at Brown University and a principal investigator for the study. "Our study highlights the importance of micronutrient diversity and the balance of health benefits and risks." The findings could be used as the basis of future clinical trials to study specific combinations of micronutrients and their impact on cardiovascular health, he said. Antioxidant supplementation has long been thought to play a role in heart health. That's because these nutrients work to reduce oxidative stress, a known contributor to many cardiovascular diseases. Heart-healthy diets like the Mediterranean diet and the Dietary Approach to Stop Hypertension (DASH) feature foods that are naturally rich in antioxidants. However, results from studies of antioxidant supplements have been inconsistent -- one reason why this approach hasn't yet been widely adopted in preventative cardiology. "Research on micronutrient supplementation has mainly focused on the health effects of a single or a few vitamins and minerals," Liu said. "We decided to take a comprehensive and systematic approach to evaluate all the publicly available and accessible studies reporting all micronutrients, including phytochemicals and antioxidant supplements and their effects on cardiovascular risk factors as well as multiple cardiovascular diseases." The researchers looked at randomized, controlled intervention trials evaluating 27 different types of antioxidant supplements. They found strong evidence that several offered cardiovascular benefit. These included omega-3 fatty acid, which decreased mortality from cardiovascular disease; folic acid, which lowered stroke risk; and coenzyme Q10, an antioxidant sometimes marketed as CoQ10, which decreased all-cause mortality. Omega-6 fatty acid, L-arginine, L-citrulline, Vitamin D, magnesium, zinc, alpha-lipoic acid, melatonin, catechin, curcumin, flavanol, genistein and quercetin also showed evidence of reducing cardiovascular risk. Not all supplements were beneficial. Vitamin C, Vitamin D, Vitamin E and selenium showed no effect on long-term cardiovascular disease outcomes or type-2 diabetes risk. And beta carotene supplements increased all-cause mortality. According to the researchers, the findings point to the need for more personalized, precision-based dietary interventions that involve specific combinations of beneficial supplements. Further study is needed, including large, high-quality interventional trials to investigate the long-term effects of certain micronutrients on health. "Identifying the optimal mixture of micronutrients is important, as not all are beneficial, and some may even have harmful effects," Liu said.

100 Deals associated with L-Citrulline

External Link

KEGG	Wiki	ATC	Drug Bank
D07706	L-Citrulline	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia, Sickle Cell	Phase 3	United States	Asklepion Pharmaceuticals LLC	25 Jul 2025
Vaso-occlusive crisis	Phase 3	United States	Asklepion Pharmaceuticals LLC	25 Jul 2025
Acute Lung Injury	Phase 3	United States	Asklepion Pharmaceuticals LLC	01 Aug 2016
Acute Lung Injury	Phase 3	Austria	Asklepion Pharmaceuticals LLC	01 Aug 2016
Acute Lung Injury	Phase 3	Germany	Asklepion Pharmaceuticals LLC	01 Aug 2016
Acute Lung Injury	Phase 3	Israel	Asklepion Pharmaceuticals LLC	01 Aug 2016
Heart Septal Defects, Atrial	Phase 3	United States	Asklepion Pharmaceuticals LLC	01 Aug 2016
Heart Septal Defects, Atrial	Phase 3	Austria	Asklepion Pharmaceuticals LLC	01 Aug 2016
Heart Septal Defects, Atrial	Phase 3	Germany	Asklepion Pharmaceuticals LLC	01 Aug 2016
Heart Septal Defects, Atrial	Phase 3	Israel	Asklepion Pharmaceuticals LLC	01 Aug 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2023	Not Applicable	COVID-19 endothelin-1 \| E-selectin \| ICAM-1 ... View more	48	L-citrulline supplementation	fpsntkwjlu(kkeykdjpau) = evazxmypjx qwezqwpqgt (colidbpxmm, -0.45 to -0.003)	Positive	20 May 2023
NCT04570384 (CTgov)	Phase 2	Respiratory Failure \| COVID-19	65	L-Citrulline (IV L-Citrulline (Turnobi) Arm)	slgpulfjyv(geghdyupvx) = yxfqzutiot zhbezglqrq (bgbloegxuq, 143.73) View more	-	22 Feb 2023
NCT04570384 (CTgov)	Phase 2	Respiratory Failure \| COVID-19	65	Placebo (Placebo Arm)	slgpulfjyv(geghdyupvx) = yqzehjxdkn zhbezglqrq (bgbloegxuq, 62.44) View more	-	22 Feb 2023
NCT03542812 (Pubmed \| Paediatr Drugs)	Early Phase 1	Bronchopulmonary Dysplasia \| Pulmonary Arterial Hypertension	16	L-Citrulline	zuzvgbwqjh(fhliasnvli) = skgcbcorpf iamqecvlxj (nhwrycxqjr ) View more	-	31 Oct 2022
NCT01120964 (CTgov)	Phase 1/2	Atrioventricular Septal Defect \| Heart Septal Defects, Atrial \| Heart Septal Defects, Ventricular	22	Intravenous L-Citrulline (Intravenous L-Citrulline)	qnvgzgfyfv(dsdxbojonf) = crvwjmokce qhmwmcucor (moifdvulrl, 569.89) View more	-	21 Jun 2022
NCT01120964 (CTgov)	Phase 1/2		22	Placebo of Intravenous L-Citrulline (Placebo of Intravenous L-Citrulline)	qnvgzgfyfv(dsdxbojonf) = vyndsoyshj qhmwmcucor (moifdvulrl, 7.5) View more	-	21 Jun 2022
NCT02214290 (CTgov)	Not Applicable	Hypertension	16	Placebo	dmwklhbljv(lvyxwrrjlu) = bvkzovnrxd gttwqzfmot (txccopukkz, 1) View more	-	29 Dec 2020
NCT01715844 (Pubmed \| JCI Insight)	Not Applicable	Asthma	41	L-citrulline 15g/day	kedqomaztm(llwvbmdpda) = szjwqoiyzh jakokfcznq (ibzdcuzdrr, -11 to 132) View more	-	19 Dec 2019
NCT01474863 (CTgov)	Phase 2	Acute Lung Injury \| Sepsis	72	Low Dose Citrulline (Low Dose Citrulline)	mbktlahoxk(ftsmxxplky) = sevtdufsft yizybpkdao (fnuujmqdlu, 28.8) View more	-	05 Jun 2017
NCT01474863 (CTgov)	Phase 2	Acute Lung Injury \| Sepsis	72	Placebo (Placebo)	mbktlahoxk(ftsmxxplky) = vansywifnk yizybpkdao (fnuujmqdlu, 30.9) View more	-	05 Jun 2017
NCT02314689 (CTgov)	Phase 1	Hemoglobin SC Disease \| Anemia, Sickle Cell	4	Intravenous (IV) citrulline	eutwpedpai = swwqhemodx jneqbwwtrj (xtkfpqbbkn, mdbbntkfis - etmirruheh)	-	07 Mar 2016
Pubmed \| J Nutr	Not Applicable	Fetal Growth Retardation	-	L-Citrulline	numcvggnoo(ooqxjepfei) = nkjozsyegr jcqyfzwpve (ltxeowmxja )	-	01 Mar 2016
Pubmed \| J Nutr	Not Applicable	Fetal Growth Retardation	-	L-Citrulline	numcvggnoo(ooqxjepfei) = eejemtxnpj jcqyfzwpve (ltxeowmxja )	-	01 Mar 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis